Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

Karnataka’s HPV vaccination plan revived under Centre’s national rollout

March 04, 2026 4 min read Social Issues Polity & Governance Science & Technology GS2 (Health) GS3 (Science & Technology)
On This Page ▼

What Happened

  • Prime Minister Narendra Modi launched India's national HPV (Human Papillomavirus) vaccination campaign on February 28, 2026, from Ajmer, integrating it into the Universal Immunisation Programme (UIP).
  • The campaign targets approximately 1.15 crore 14-year-old girls annually across all States and Union Territories, with vaccination to be administered free of cost at government health facilities.
  • Karnataka, which had earlier piloted its own school-based HPV vaccination programme, has been revived under this national rollout as one of 9 states in the second phase of implementation.
  • The vaccine being used is CERVAVAC, an indigenous quadrivalent HPV vaccine developed by the Serum Institute of India, priced between Rs 200–400 per dose — significantly cheaper than imported alternatives like Gardasil.
  • A three-month special drive will precede integration into routine immunisation services, with delivery through schools (Grades 5–10), health facilities, and mobile teams for out-of-school girls.

Static Topic Bridges

Universal Immunisation Programme (UIP)

India's Universal Immunisation Programme, launched in 1985 under the Expanded Programme on Immunisation, is one of the largest public health programmes in the world. It provides free vaccines against 12 vaccine-preventable diseases to children and pregnant women. Managed by the Ministry of Health and Family Welfare under the National Health Mission (NHM), the UIP has progressively expanded its basket of vaccines — from polio and BCG to pentavalent and rotavirus vaccines.

  • Covers approximately 2.6 crore newborns and 2.9 crore pregnant women annually
  • Funded primarily by the Central Government with state co-participation under NHM
  • Mission Indradhanush (2014) and Intensified Mission Indradhanush aimed to achieve full immunisation coverage for children previously unreached
  • The HPV vaccine marks the first adolescent girl-targeted addition to the UIP basket

Connection to this news: The inclusion of HPV vaccine into the UIP represents a major expansion of the programme beyond infancy to adolescent girls, establishing a school-based delivery platform for immunisation for the first time at the national level.

Cervical Cancer Burden and HPV Biology

Cervical cancer is the second most common cancer among women in India, accounting for over 1.2 lakh new cases and nearly 80,000 deaths annually (GLOBOCAN 2022 data). Persistent infection with high-risk HPV types — particularly types 16 and 18 — accounts for over 80% of cervical cancer cases in India. HPV is a sexually transmitted virus; vaccination before exposure (ideally ages 9–14) provides the highest degree of protection. The quadrivalent CERVAVAC vaccine targets HPV types 6, 11, 16, and 18.

  • India bears approximately 25% of the global cervical cancer burden
  • HPV types 16 and 18 are responsible for about 70% of all cervical cancers worldwide
  • Single-dose schedule (for the 14-year age group) simplifies delivery in public health settings
  • CERVAVAC is indigenously developed under the Department of Biotechnology's partnership with Serum Institute of India, approved by DCGI in 2022

Connection to this news: Karnataka's prior state-level HPV pilot demonstrated feasibility of school-based delivery; the national rollout now standardises this approach, and CERVAVAC's affordable pricing makes public procurement at scale fiscally viable.

Centre-State Dynamics in Health Delivery

Health is a State subject under Schedule VII (List II) of the Indian Constitution. However, public health programmes of national importance — such as immunisation — are administered by the Centre through Centrally Sponsored Schemes under the National Health Mission, with states responsible for last-mile implementation. The success of vaccination campaigns hinges on state-level machinery, including Auxiliary Nurse Midwives (ANMs), ASHA workers, and school health infrastructure.

  • NHM operates as a Centrally Sponsored Scheme with a 60:40 Centre-State funding ratio (90:10 for special category states)
  • States like Karnataka, Tamil Nadu, Sikkim, and Punjab had already launched their own HPV pilots before the national programme
  • Phase-wise rollout (9 states in Phase 2) allows iterative learning and scale-up

Connection to this news: Karnataka's early adoption of an HPV programme at the state level — and its subsequent alignment with the Central rollout — illustrates the interplay between state health initiative and Central programme consolidation in Indian cooperative federalism.

Key Facts & Data

  • Launch date: February 28, 2026, from Ajmer, Rajasthan
  • Target group: 14-year-old girls (approximately 1.15 crore annually)
  • Vaccine: CERVAVAC (quadrivalent — HPV types 6, 11, 16, 18), made by Serum Institute of India
  • Cost: Rs 200–400 per dose (public market price); free under UIP
  • National procurement market opened: Rs 1,300 crore annually
  • Karnataka: among Phase 2 states (alongside Andhra Pradesh, Goa, Maharashtra, Telangana, Tripura, Uttarakhand, Daman & Diu, Dadra & Nagar Haveli)
  • India's cervical cancer burden: 1.2 lakh new cases, ~80,000 deaths per year (GLOBOCAN 2022)
  • Delivery mechanism: Schools (Grade 5–10), health facilities, mobile teams for out-of-school girls